DarioHealth Corp. DRIO

DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced a new contract with a leading health plan in New Jersey, one of the largest in the state representing approximately 1.5 million covered lives. The agreement was secured through Dario's strategic channel partnership with Amwell and is expected to launch and begin generating revenue in the first quarter of

DarioHealth Corp (DRIO) reports improved gross margins and reduced losses while navigating a revenue dip from pharma exit and implementation timing.

Moby summary of DarioHealth Corp.'s Q2 2026 earnings call

DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced financial results for the second quarter ended June 30, 2026.

The Joint (JYNT) delivered earnings and revenue surprises of -109.09% and +3.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced it has further expanded its provider-backed cardiometabolic platform with the launch of Dario Women™ and Dario Sleep™. The two new programs address important drivers of cardiometabolic health through an integrated care experience combining AI-powered engagement, behavioral support and access to licensed h

DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leading artificial intelligence ("AI")-powered healthcare technology company transforming the management of chronic conditions, announced today that it will release its financial results for the 2nd quarter ended June 30th, 2026 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Tuesday, August 11th, 2026, before the market opens.

DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the launch of Dario's Integrated GLP-1 Program, the first commercial offering built on the Company's recently announced collaboration with Beluga Health ("Beluga").

DarioHealth Corp. (NASDAQ: DRIO) (the "Company," "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced that it has entered into securities purchase agreements with current long term Dario institutional investors as well as new fundamental investors for the purchase and sale of 3,454,559 shares of common stock (or common stock equivalents in lieu thereof), at a price of $6.80 per share, in a registered dire

DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced another Fortune 50 employer has selected Dario to provide its integrated digital cardiometabolic care platform for employees living with diabetes and/or hypertension. The program will be available to more than 100,000 eligible employees and is expected to launch in Fall 2026. "Winning another Fortune 50 employer underscores the growing recognition that integrated chronic condition management delivers